 |
Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial Results
05/16/13
|
19.0 KB |
|
| |
CORAL GABLES, Fla., May 16, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced financial results for the three month period ended...
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2012 Financial Results
04/02/13
|
18.7 KB |
|
| |
CORAL GABLES, Fla., April 2, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, today reported financial results for the fourth qua...
|
|
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse(TM)
03/27/13
|
13.7 KB |
|
| |
CORAL GABLES, Fla., March 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, announced today that, on March 25, 2013, the indep...
|
|
Catalyst Pharmaceutical Partners to Present at 25th Annual ROTH Conference
03/07/13
|
12.9 KB |
|
| |
CORAL GABLES, Fla., March 7, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Patrick J. McEnany, Catalyst's Chief Executive Officer, and Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will be presenting an overview of the company and its progress in key programs at the 25th Annual R...
|
|
Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations
03/05/13
|
13.1 KB |
|
| |
CORAL GABLES, Fla., March 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is pleased to announce today the appointment of Bernardino Mosquera, ...
|
|
Catalyst Pharmaceutical Partners Launches New Website
02/21/13
|
13.3 KB |
|
| |
CORAL GABLES, Fla., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is pleased to announce the launch of its newly designed website. The ...
|
|
Catalyst Pharmaceutical Partners Provides Update on Research and Development Pipeline
02/11/13
|
20.9 KB |
|
| |
CORAL GABLES, Fla., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, today provided an update on its research and development pipeline.
...
|
|
Catalyst Pharmaceutical Partners to Present at 15th Annual BIO CEO & Investor Conference
02/05/13
|
12.2 KB |
|
| |
CORAL GABLES, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that the company will present at the 15th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, PhD, C...
|
|
Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement
12/27/12
|
13.4 KB |
|
| |
CORAL GABLES, Fla., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it received a Nasdaq Staff Deficiency Letter, dated December 24, 2012, indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listi...
|
|
Catalyst Pharmaceutical Partners Announces Automatic Conversion of $5 Million Promissory Note Into Shares of Common Stock
12/11/12
|
13.6 KB |
|
| |
CORAL GABLES, Fla., Dec. 11, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has issued 6,666,667 shares (the "Shares") of its authorized but unissued common stock to BioMarin Pharmaceutical, Inc. ("BioMarin") upon the automatic conversion of the $5 million loan that Catalyst received from BioMa...
|
|
Catalyst Pharmaceutical Partners Announces Third Quarter 2012 Financial Results
11/15/12
|
20.0 KB |
|
| |
CORAL GABLES, Fla., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the third quarter and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $2,621,535, or $0.08 per basic and diluted share, compared ...
|
|
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II(b) Trial for Cocaine Addiction
11/08/12
|
14.4 KB |
|
| |
CORAL GABLES, Fla., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced top-line results from its U.S. Phase II(b) clinical trial evaluating the use of CPP-109 (vigabatrin) to treat cocaine addiction. The data from the trial showed that CPP-109 did not meet the primary endpoint -- that a significant...
|
|
Catalyst Pharmaceutical Partners and BioMarin Pharmaceutical Enter Into Strategic Collaboration for Firdapse(TM) in North America
10/31/12
|
21.1 KB |
|
| |
BioMarin to Make $5 Million Strategic Equity Investment in Catalyst
Catalyst Licenses North American Rights to Firdapse™, a Phase III Orphan Drug for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Expects Top-Line CPP-109 Phase II(b) Data During First Half of November
CORAL GABLES, Fla., Oct. 31, ...
|
|
Catalyst Pharmaceutical Partners Updates Guidance on Timing of Top-Line Data From CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction
09/26/12
|
15.9 KB |
|
| |
CORAL GABLES, Fla., Sept. 26, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has been advised by the Department of Veterans Affairs Cooperative Studies Program (VACSP) that the availability of top-line results from Catalyst's CPP-109 (vigabatrin) Phase II(b) trial for cocaine addiction will be ...
|
|
Catalyst Pharmaceutical Partners Announces Commencement of CPP-109 Investigator-Sponsored Study in Patients With Treatment Refractory Tourette's Disorder
09/24/12
|
15.2 KB |
|
| |
CORAL GABLES, Fla., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that researchers at Mount Sinai School of Medicine in New York have commenced a safety and tolerability trial of vigabatrin in young adults with treatment refractory Tourette's Disorder (TD) to evaluate whether CPP-109 (vigaba...
|
|
Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 14th Annual Healthcare Conference
09/06/12
|
13.4 KB |
|
| |
CORAL GABLES, Fla., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Patrick J. McEnany, Chief Executive Officer, will be presenting at Rodman & Renshaw's 14th Annual Healthcare Conference, which is being held on September 10-11, 2012 at The Waldorf=Astoria in New York, NY.
The pres...
|
|
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced $6 Million Registered Direct Offering
08/30/12
|
15.6 KB |
|
| |
CORAL GABLES, Fla., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has closed its previously announced offering of (i) 4.0 million shares of the Company's common stock, and (ii) warrants to purchase an aggregate of 1.2 million shares of the Company's common stock, in a registered direc...
|
|
Catalyst Pharmaceutical Partners, Inc. Raises $6 Million in Registered Direct Offering
08/28/12
|
15.0 KB |
|
| |
CORAL GABLES, Fla., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has entered into definitive agreements to sell (i) 4.0 million shares of the Company's common stock, and (ii) common stock purchase warrants to purchase an aggregate of 1.2 million shares of the Company's common stock, ...
|
|
Catalyst Pharmaceutical Partners Announces Second Quarter 2012 Financial Results
08/15/12
|
20.2 KB |
|
| |
CORAL GABLES, Fla., Aug. 15, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the second quarter and six months ended June 30, 2012. For the three months ended June 30, 2012, the Company reported a net loss of $289,080, or $0.01 per basic and diluted share, compared to a net los...
|
|
Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule
08/03/12
|
13.1 KB |
|
| |
CORAL GABLES, Fla., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has received notice from the NASDAQ Stock Market ("NASDAQ") confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market.
As ...
|
|
|
Print